BIOMARIN PHARMACEUTICAL INC
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On August 16, 2024, Dr. Henry J. Fuchs advised BioMarin Pharmaceutical Inc. (the “Company”) that he has elected to retire from the Company effective March 3, 2025 (the “Retirement Date”).
He will continue in his current role until Dr. Greg Friberg assumes the position of Executive Vice President, Chief Worldwide Research and Development Officer, which is expected on September 30, 2024.
Extracted from this filing and checked against the source text.
Henry J. Fuchs retired as Executive Vice President, Chief Worldwide Research and Development Officer at BIOMARIN PHARMACEUTICAL INC.
On August 16, 2024, Dr. Henry J. Fuchs advised BioMarin Pharmaceutical Inc. (the “Company”) that he has elected to retire from the Company effective March 3, 2025 (the “Retirement Date”).View on SEC.gov
Greg Friberg was appointed as Executive Vice President, Chief Worldwide Research and Development Officer at BIOMARIN PHARMACEUTICAL INC.
He will continue in his current role until Dr. Greg Friberg assumes the position of Executive Vice President, Chief Worldwide Research and Development Officer, which is expected on September 30, 2024.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.